NCT03422172 - A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

April 20, 2020

Study Completion Date

April 20, 2020

Conditions

HIV Infections

Interventions

DRUG

Oral CAB

CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.

DRUG

CAB LA

CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.

Trial Locations (3)

100069

GSK Investigational Site, Beijing

201508

GSK Investigational Site, Shanghai

310000

GSK Investigational Site, Hangzhou